Browsing: Biopharma

Clinical-stage radiopharmaceutical companyAdvanCell, which is developing targeted therapies for cancer, appointed Sean Cassidy as chief financial officer (CFO). Cassidy joins the company as AdvanCell advances its clinical pipeline toward commercialization, bringing more than 20 years of industry leadership experience in both private and public life sciences companies.

The first half of 2026 has brought artificial intelligence (AI) from experimental curiosity to an operational imperative across finance and accounting. Yet, as organizations race to adopt these tools, leaders are confronting a complex landscape defined by shifting valuation expectations, investor skepticism, pressing talent shortages, and the foundational challenge of data governance. Here’s a look…

This week, Informa’sFinance and Accounting for Biosciencetakes place in Boston, offering pharma professionals a place to learn, network, and discuss a variety of relvant topics. These include sessions on the 2027 finance outlook; controllership concerns; SEC and FASB presentations; and sessions for pre-commercial and commercial stage biopharma finance groups.

Earlier this month, the British Business Bank made a £75 million ($101 million) commitment to Molten Ventures’ new Growth Fund. The funding is intended to help the venture capitalist (VC) firm reach its £350 million ($473 million) target to back UK and European technology companies at Series B and beyond.

Massachusetts’ biopharma industry lost thousands of jobs last year, but investment in the sector has rebounded, according to a report released Tuesday by MassBio.

The days of biotech businesses and institutions limiting their research and commercial activity to top clusters like Boston/Cambridge, MA, and the San Francisco Bay Area are passing, as the life sciences expand their horizons to regions and states not usually thought of as hotspots for the industry.

Aug. 10, 2026 /PRNewswire/ — Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today reported financial and operational results for the second quarter of 2026